DBV Technologies SA – (NASDAQ:DBVT) saw unusually-strong trading volume on Wednesday . Approximately 3,517,380 shares traded hands during trading, an increase of 1,102% from the previous session’s volume of 292,696 shares.The stock last traded at $26.23 and had previously closed at $20.86.

A number of equities analysts have recently commented on DBVT shares. Zacks Investment Research raised shares of DBV Technologies from a “hold” rating to a “buy” rating and set a $32.00 target price on the stock in a research report on Tuesday, October 24th. BidaskClub lowered shares of DBV Technologies from a “sell” rating to a “strong sell” rating in a research report on Wednesday, December 6th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of DBV Technologies in a research note on Monday, October 23rd. JMP Securities assumed coverage on shares of DBV Technologies in a research note on Friday, November 17th. They set an “outperform” rating on the stock. Finally, Societe Generale upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a research note on Tuesday, October 31st. Three analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. DBV Technologies has a consensus rating of “Hold” and a consensus price target of $49.63.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DBVT. ArrowMark Colorado Holdings LLC boosted its stake in shares of DBV Technologies by 94.9% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 2,007,684 shares of the company’s stock valued at $49,389,000 after purchasing an additional 977,491 shares in the last quarter. Perceptive Advisors LLC boosted its stake in shares of DBV Technologies by 3,604.2% during the fourth quarter. Perceptive Advisors LLC now owns 978,619 shares of the company’s stock valued at $24,075,000 after purchasing an additional 952,200 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of DBV Technologies by 10.1% during the third quarter. Janus Henderson Group PLC now owns 2,797,789 shares of the company’s stock valued at $118,738,000 after purchasing an additional 257,210 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of DBV Technologies during the third quarter valued at approximately $7,794,000. Finally, University of Notre Dame DU Lac boosted its stake in shares of DBV Technologies by 94.3% during the fourth quarter. University of Notre Dame DU Lac now owns 115,115 shares of the company’s stock valued at $2,832,000 after purchasing an additional 55,860 shares in the last quarter. Hedge funds and other institutional investors own 46.36% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “DBV Technologies (DBVT) Sees Large Volume Increase” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/02/14/dbv-technologies-dbvt-sees-large-volume-increase.html.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.